MoonLake Immunotherapeutics (MLTX)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in MoonLake Immunotherapeutics, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

MoonLake Immunotherapeutics (MLTX) has returned 41.43% so far this year and -52.29% over the past 12 months.

Based on dividend-adjusted daily data since Oct 20, 2020, MLTX's average daily return is +0.26%, while the average monthly return is +4.33%. At this rate, your investment would double in approximately 1.4 years.

Historically, 53% of months were positive and 47% were negative. The best month was Jun 2023 with a return of +87.4%, while the worst month was Sep 2025 at -87.1%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 4 months.

On a daily basis, MLTX closed higher 48% of trading days. The best single day was Jun 26, 2023 with a return of +77.6%, while the worst single day was Sep 29, 2025 at -89.9%.

MoonLake Immunotherapeutics has an annualized alpha of 78.04%, beta of 0.62, and R² of 0.01 versus S&P 500 Index. Calculated based on daily prices since October 21, 2020.

• This stock participated in 79.36% of S&P 500 Index downside but only 77.23% of its upside — more exposed to losses than it benefited from rallies.
• Beta of 0.62 may look defensive, but with R² of 0.01 this stock is largely uncorrelated with S&P 500 Index — low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R² of 0.01 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

MLTX ranks 38 for risk / return — below 38% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.

The table below present risk-adjusted performance metrics for MoonLake Immunotherapeutics (MLTX) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the MoonLake Immunotherapeutics. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the MoonLake Immunotherapeutics was 90.22%, occurring on Sep 29, 2025. The portfolio has not yet recovered.

The current MoonLake Immunotherapeutics drawdown is 70.81%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of MoonLake Immunotherapeutics over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how MoonLake Immunotherapeutics is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.